Losmapimod, a p38 MAPK inhibitor, is a promising drug developed by Fulcrum Therapeutics that is the first compound to target the underlying mechanism of FSHD by inhibiting DUX4. Phase 2 data for ...

This insight into the DUX4 regulatory pathway led the team to review existing p38/ MAPK inhibitors and identify losmapimod as a compound with the potential to address the root cause of FSHD by ...

Levitchi Benea and colleagues wanted to assess the safety and tolerability of losmapimod (Fulcrum Therapeutics), a small molecule p38 alpha/beta MAPK inhibitor, in facioscapulohumeral muscular ...

Losmapimod is a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor. Fulcrum exclusively in-licensed losmapimod from GSK following Fulcrum’s discovery of the role of p38α/β ...

Treatment with losmapimod and placebo had similar results with respect to primary, secondary endpoints. No treatment-related severe adverse events, discontinuation or deaths were recorded with ...

In light of these results, the company plans to suspend the losmapimod program in FSHD. Ready to turn the market’s comeback into steady cash flow? Grab the top 3 stocks to buy right here.

Losmapimod is a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor. Fulcrum exclusively in-licensed losmapimod from GSK following Fulcrum’s discovery of the role of p38α/β ...

Following the live webcast, an archived replay will also be available. Losmapimod is a selective p38a/ß mitogen activated protein kinase (MAPK) inhibitor. Fulcrum exclusively in-licensed losmapimod ...